Diagnostics and Imaging

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

10 July 2023

Our new report contains a wealth of evidence for clinical value and cost-saving potential of next-generation sequencing (NGS) testing in lung cancer, and recommends that increased uptake requires focus on reimbursement, national standardisation, and new infrastructure

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

19 May 2023

In this report, we propose a novel payment model that will incentivise broader value demonstration for diagnostics for antibiotics that could inform longer-term financing and reimbursement arrangements and guide prescribing behaviours.

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

2 June 2023

In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for widespread access.

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

5 July 2016

“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

1 April 2012

Diagnostics not only facilitate health gain and cost savings, but also provide information to inform patients’ decisions on interventions and to clarify how their behaviour may…

Early Diagnosis of Cancer of the Cervix

1 July 1968

Cancer < 1 min read|01/07/1968 ALTHOUGH cervical cancer causes only 1 per cent of female deaths, it is responsible for almost one quarter of all deaths…